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HPV vaccinations—possibly necessary but not suﬃ  cient
Using country speciﬁ c epidemiological-economic 
model ling, Mark Jit and colleagues1 show how the 
adoption of safe, well tolerated,2 immunogenic, and 
eﬀ ective vaccination3 of 12-year-old girls against the 
cancer-causing human papillomaviruses (HPV)4 will 
prevent hundreds of thousands of cases of, and deaths 
from, cervical cancer worldwide.  
By synergistically combining epidemiological with 
economic data, this study estimates the gold-standard 
cost per disability adjusted life-year (DALY) of girls 
vaccinated in 179 countries worldwide. This global 
study has advantages over both the many previously 
reported studies based on individual country or 
individual countries within a single region, and over 
a worldwide study that analysed the results only at a 
regional level (where decisions are not made).
However, to focus on reproducible simplicity, the 
authors were forced to omit many issues such as 
calculations from a social perspective including lost 
work productivity, decreases in condylomas as a result of 
quadravalent vaccines, possible decreases5 in non-cervical 
cancers that might be associated with the HPV virus,6 
possible cross-protection against genotypes7 other than 
HPV 16/18, the (admittedly complicated) eﬀ ect of herd 
immunity, gains in use because of fewer lesion removals 
in countries where screening programmes already exist 
in parallel, and the possibility that a two-dose schedule 
might be as eﬀ ective as three doses.8
Also omitted, for understandable reasons of simplicity 
and clarity, are necessary comparisons of vaccination 
with other potential interventions that would reduce 
the burden of cervical cancer in regions such as sub-
Saharan Africa and southeast Asia—eg, low technology 
interventions including visual inspection with acid or a 
one-oﬀ  PAP smear programme at 40 years of age.9  
Generally, transparency regarding the costs of vaccine 
manufacturing and vaccine procurements obtained 
by individual high-income countries is insuﬃ  cient in 
countries other than the USA. However, it is generally 
known that many developed countries acquire their 
vaccines at a discount of 50–75% greater than USA 
costs. Jit and colleagues1 show vaccination to be very 
cost eﬀ ective in 87% of countries. This high value 
therefore actually represents a conservatively low 
estimate because Jit and colleagues’ model set vaccine 
prices in high-income countries to the US retail vaccine 
price of around $130 per dose. Thus, many developed 
countries that fell only into the cost-eﬀ ective category 
could possibly be reclassiﬁ ed as being very cost eﬀ ective. 
Perhaps, even some of the low-incidence, high-income 
oil states of Saudi Arabia and the United Arab Emirates 
Gulf States would also be reclassiﬁ ed from not cost 
eﬀ ective to cost eﬀ ective if their true potential costs of 
vaccine procurement were known.
Availability of the HPV vaccination has increased 
the number of available strategies in the ﬁ ght against 
cervical cancer and complicated the choice of which 
interventions to adopt to reduce the burden. One must 
not lose sight of the fact that the vaccine only protects 
against two (or four) genotypes that are associated 
with 50–90% of cervical cancer in a speciﬁ c region. If the 
vaccine is adopted in any country, consideration must be 
given to supplement the vaccination with the initiation 
or continued provision (albeit at a diﬀ erent frequency) 
of one of the many screening options available. 
The anticipated 9-valent vaccine,10 if successful and 
adopted, will increase the range of covered genotypes 
by 10–20%, and therefore reduce the need for screening 
in individuals that have been vaccinated still further. Of 
course, screening tests will still need to be provided for 
unvaccinated populations, because even in developed 
countries the cost of providing a catch-up programme 
(eg, vaccinating girls aged 14–26 years) is likely to be 
prohibitive.
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